Insider buying last 90 days
No open-market insider purchases were filed for NVS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NVS insider filing, plotted on the chart in Gekko.Open NVS in Gekko
Gekko Brief
AI summaryNov 4 closeNovartis shares have moved this week on a mix of Q3 2026 results and pipeline news. The company raised full-year core operating income guidance after reporting 4% constant currency sales growth and 10% core operating income growth, with priority brands up 29%, led by Kisqali, Kesimpta and Pluvicto. Rhapsido peak sales guidance was increased to over $4 billion combined, and a slower Entresto decline eased concerns despite a $1.9 billion write-down. Offsetting this, Novartis terminated its $800 million BioArctic brain-delivery collaboration after 14 months, and an experimental heart drug, pelacarsen, failed to reduce heart attack and stroke risk in testing. A labeling update for Lamprene was also approved, though it carries limited bearing on current sales.
Novartis closed at $164.98, up 3.6%, with the stock trading above both its 50-day ($148.58) and 200-day ($152.08) moving averages. The GekkoIndex reads 47.2, placing it in the Neutral zone. Price sits 16.1% below Gekko Fair Value of $196.66.
The next earnings date falls on 3 February 2027, outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in their respective windows, though one billionaire holder is recorded. Seasonality over the next 20 trading days has averaged +3% across 5 years, with gains in 3 of them. Analyst consensus stands at 2 buy and 2 hold ratings among 4 firms, with a consensus target of $154.80.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Novartis price vs fair value
Close $164.98200-day averageGekko Fair Value $196.66
Novartis quick facts
- Market cap
- $311.6B
- P/E ratio
- 30.8
- Forward P/E
- 16.1
- EPS, TTM
- $5.24
- Revenue, TTM
- $57.36B
- Profit margin
- 17.5%
- Dividend yield
- 2.93%
- Beta
- 0.46
- Volume
- 1.74M avg 2.05M
- 1-year return
- +33.2%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.1%
- 50-day average
- $148.58
- 200-day average
- $152.08
- Next earnings
- Feb 3 before open
- Shares outstanding
- 1.89B
Novartis swing-trade checklist
Novartis scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $164.98 sits between the 50-day ($148.58) and 200-day ($152.08) averages, or the averages disagree.
See the chart - GekkoIndexmixed
47.2, Neutral
Reading 47.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
16.1% below
Price is 16.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 90 days
Next report Feb 3, 2027, 90 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.0% on average
From this point in the calendar, the next 20 trading days averaged +3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Novartis stock chart and price history
Novartis closed at $164.98 on Nov 4, 2026, +33.2% over the past year, inside a 52-week range of $123.24 to $170.46.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +17.2%
- 3 months
- +7.0%
- 6 months
- +11.2%
- 1 year
- +33.2%
The full NVS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NVS in Gekko
Follow Novartis through every session
Put NVS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NVS in GekkoFree for 7 days. No credit card required.
About Novartis
Novartis develops, manufactures, and markets healthcare products, with much of its work centered on prescription medicines used in treating cancer, immune-related conditions, neurological disorders, and heart and blood vessel diseases. Alongside these newer treatments, the company also maintains a line of long-established medicines and various specialized therapies for other conditions.
As a holding company, Novartis operates through its portfolio of healthcare-related businesses, drawing revenue from the sale of its medicines and therapies rather than a single product line.
Novartis traces its founding to February 29, 1996, and keeps its headquarters in Basel, Switzerland. Its shares trade under the ticker NVS.
- Sector
- Health technology
- Website
- novartis.com
Novartis GekkoIndex: the smart money zone
Novartis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.2, in the Neutral zone, down 1.5 points over five sessions.
47.2Neutral
Down 1.5 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | −0.1% | −0.6% | ||
| Accumulation | 164 | +1.0% | +3.5% | ||
| Neutral (current zone) | 401 | +0.3% | +1.1% | ||
| Distribution | 52 | +0.1% | +0.6% | ||
| Selling | 0 | Not available | |||
Average NVS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the NVS price, zone by zone.Track NVS in Gekko
Is Novartis stock overvalued? Gekko Fair Value
Novartis trades 16.1% below Gekko Fair Value of $196.66, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Novartis shares are worth, recalculated every trading day.
$196.66
Gekko Fair Value, Nov 4, 2026
16.1% Undervalued
At the end of Aug 2026 the price was 24.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NVS in Gekko
Novartis insider and Congress trading
No open-market insider purchases were filed for Novartis, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NVS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NVS, plotted on the chart in Gekko.Open NVS in Gekko
Buybacks
Novartis has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $1.70B
- As a share of market cap
- 0.54%
- Trailing four quarters
- $6.25B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds NVS.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Novartis earnings: next date and track record
Novartis reports on Feb 3, 2027, before the open (90 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Feb 3, 2027
Expected before the open, 90 days away
- EPS estimate
- $2.23
- Revenue estimate
- $14.69B
6 of 8reports beat the EPS estimate
±2.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 27, 2026 AI summary
- What they said
- Novartis Q3 2026 delivered 4% constant currency sales growth and 10% core operating income growth, prompting an upgrade to full-year bottom line guidance. Priority brands grew 29%, led by Kisqali (+37%), Kesimpta (+22%), and Pluvicto (+20%). Key pipeline milestones included Repsido FDA approval, Pluvicto approvals in US and China for HSPC, Blabrasib European filing, and Delzota FDA priority review for DMD.
- Guidance
- Novartis upgraded full-year 2026 bottom line guidance following strong Q3 performance. Management expects continued share gains for Kisqali in early breast cancer and Pluvicto in mCRPC pre-taxane settings, with PSMA edition launch momentum building.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 27, 2026 | $2.46 est $2.25 | $14.52B est $14.53B | +1.5% |
| Jul 21, 2026 | $2.41 est $2.20 | $14.41B est $14.07B | +2.4% |
| Apr 28, 2026 | $1.65 est $1.65 | $13.11B est $13.44B | −0.9% |
| Feb 4, 2026 | $2.03 est $1.99 | $13.34B est $13.70B | +2.7% |
| Oct 28, 2025 | $2.25 est $2.26 | $14.36B est $13.64B | −5.7% |
| Jul 17, 2025 | $2.42 est $2.38 | $14.28B est $13.94B | −3.5% |
| Apr 29, 2025 | $2.28 est $2.12 | $13.62B est $13.90B | +0.8% |
| Jan 31, 2025 | $1.98 est $1.76 | $13.56B est $12.84B | +0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Novartis stock forecast and analyst price targets
Analysts’ average 12-month price target for Novartis is $154.80, −6.2% from the last close, from 4 firms rating the stock in the last 90 days.
$154.80consensus 12-month target, −6.2% from the last close
Now $164.98Avg $154.80
Low $136High $180
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 28 | Morgan Stanley | $163 | −1.2% |
| Oct 27 | Bank of America Securities | — | — |
| Oct 12 | Bank of America Securities | $180.82 | +9.6% |
| Oct 6 | Morgan Stanley | $156 | −5.4% |
| Oct 5 | Bank of America Securities | — | — |
+1.1%average 20-day move after past Neutral readings
+3.0%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Novartis seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Novartis averaged +3.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 3 of 5 |
| Next 10 trading days | +0.2% | 3 of 5 |
| Next 15 trading days | +1.4% | 3 of 5 |
| Next 20 trading days | +3.0% | 3 of 5 |
| Next 30 trading days | +3.3% | 4 of 5 |
For scale, NVS’s typical 20-trading-day move in either direction is about 4.1%.
Novartis market cap and key statistics
Novartis’s market cap is $311.6B, with a P/E ratio of 30.8 and revenue of $57.36B over the last twelve months.
Valuation
- Market cap
- $311.6B
- P/E ratio
- 30.8
- Forward P/E
- 16.1
- EPS, TTM
- $5.24
- Gekko Fair Value
- $196.66
Trading
- Volume
- 1.74M
- Avg volume, 20 days
- 2.05M
- 52-week high
- $170.46
- 52-week low
- $123.24
- Shares outstanding
- 1.89B
Financials
- Revenue, TTM
- $57.36B
- Profit margin
- 17.5%
- Return on equity
- 24.3%
- Quarterly earnings growth, YoY
- −68.8%
Risk and income
- Beta
- 0.46
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.1%
- Dividend yield
- 2.93%
Novartis stock news this week
Coverage of Novartis this week reads negative: 3 positive, 4 neutral and 5 negative headlines.
- FDA Approval for LAMPRENE issued to NOVARTISQuantisnow, Nov 3
- Novartis: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool, Nov 3
- Novartis AG (NOT.HA) Seasonal returns chart - Yahoo FinanceYahoo Finance Singapore, Nov 3
- Stock Watch: Raised Outlook And Slower Entresto Decline Ease Novartis NervesScrip, Nov 3
- Novartis Exits $800M BioArctic Brain-Delivery Pact After 14 MonthsBigGo Finance, Nov 3
- Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol targetReuters, Nov 2
Novartis stock FAQ
What is Novartis’s market cap?
Novartis’s market cap is $311.6B at the Nov 4, 2026 close of $164.98, with 1.89B shares outstanding. The shares trade on a P/E ratio of 30.8.
What is the Novartis stock forecast?
The consensus analyst 12-month price target for Novartis is $154.80, −6.2% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Novartis stock overvalued or undervalued?
On Gekko’s estimate Novartis is undervalued: the Nov 4, 2026 close of $164.98 is 16.1% below Gekko Fair Value of $196.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Novartis report earnings next?
Novartis is expected to report on Feb 3, 2027, before the market opens (90 days away). Analysts expect earnings of $2.23 per share on revenue of $14.69B. Novartis beat the earnings estimate in 6 of its last 8 reports, moving 2.3% on average across the report.
What is Novartis’s 52-week high and low?
Novartis’s 52-week high is $170.46 and its 52-week low is $123.24; it closed at $164.98 on Nov 4, 2026, +33.2% over the past year.
Is Novartis stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Novartis the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.